Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer
Open Access
- 11 May 2020
- journal article
- research article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (5)
- https://doi.org/10.1042/bsr20200349
Abstract
In recent years, many studies on the relationship between the expression of microRNA-126(miR-126) and the diagnostic and prognostic value of non-small cell lung cancer (NSCLC)have been made, but the results were still controversial.The aim is to explore the expression of miR-126 and the diagnosis and prognosis value of NSCLC, and to provide relevant evidence for clinical diagnosis and treatment. literature related to miR-126 and NSCLC were searched in PubMed, Embase, Cochrane Library, Web of Science, CNKI and Wanfang from the inception to February 2020. Stata 15.0 was used for meta-analysis. The diagnostic value data were used to calculate the pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and the prognostic value data were used to calculate the pooled risk ratio (HR) of overall survival (OS) and its 95% confidence interval(95%CI).Thirteen studies were included, among which 5 were related to diagnosis containing 439 patients and 463 healthy controls,and 8 related to prognosis containing 1102 patients. The results of miR-126 expression and diagnostic value of NSCLC showed that the pooled sensitivity was 0.83 (95%CI: 0.59~0.94), specificity=0.83(95%CI: 0.71~0.90), PLR=4.78(95%CI: 2.97~7.69), NLR=0.20(95%CI: 0.08~0.54), DOR=23.48(95%CI: 7.87~70.10), and the area under the SROC curve was 0.89 (95%CI:0.86~0.91). The results of prognostic value indicated that The expression of miR-126 was related to the OS of NSCLC (HR=0.79 ,95%CI:0.63~0.98). In conclusion, The expression of miR-126 has medium diagnostic value, and it’s related to the prognosis of patients with NSCLC,with poor prognosis of miR-126 low expression.Keywords
This publication has 34 references indexed in Scilit:
- SIRT1 Activators Suppress Inflammatory Responses through Promotion of p65 Deacetylation and Inhibition of NF-κB ActivityPLOS ONE, 2012
- MicroRNA-126 Inhibits Tumor Cell Growth and Its Expression Level Correlates with Poor Survival in Non-Small Cell Lung Cancer PatientsPLOS ONE, 2012
- Clinical significance of circulating miR-126 quantification in malignant mesothelioma patientsClinical Biochemistry, 2012
- Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancerLung Cancer, 2011
- Plasma microRNAs as potential biomarkers for non-small-cell lung cancerLaboratory Investigation, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell linesBiochemical and Biophysical Research Communications, 2008
- Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer GuidelineJournal of Clinical Oncology, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005